Grass-pollen allergy immunotherapy sublingual - Lofarma

Drug Profile

Grass-pollen allergy immunotherapy sublingual - Lofarma

Alternative Names: LAIS® Grass Tablets

Latest Information Update: 07 Apr 2015

Price : $50

At a glance

  • Originator Lofarma S.p.A
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 25 Mar 2015 Phase-III clinical trials in Allergic rhinoconjunctivitis in Hungary and Italy (Sublingual) (EudraCT2014-004431-38)
  • 26 Feb 2013 Phase-III clinical trials in Allergic rhinoconjunctivitis in Germany (Sublingual)
  • 21 Mar 2012 Lofarma completes the SMART-5 phase II trial in Allergic rhinoconjunctivitis and Allergic rhinitis in Germany (EudraCT 2011-002174-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top